Health economic outcomes of a minimal monitoring approach to providing HCV therapy
Open Access
- 21 April 2025
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 9 (5)
Abstract
Background: The ACTG A5360 trial demonstrated that HCV treatment without planned on-treatment monitoring is safe and effective. We report the health economic outcomes of MINMON. Methods: A5360 was a 5-country, single-arm trial providing sofosbuvir/velpatasvir to people with HCV infection with no planned clinic visits between treatment initiation and week 24 sustained virologic response (SVR) evaluation. Trial records included planned/and most unplanned lab tests and visits. Participants completed a 4-week recall questionnaire at weeks 0, 24, 48, and 72 reporting hospital nights, emergency department visits, and ambulatory visits. We tabulated consumption and multiplied units of consumption by country-specific cost. We report the cost and cost per SVR of MINMON (2020 US$) from program and health sector perspectives. Sensitivity analyses compared MINMON costs to the standard of care (SoC). We consulted in-country experts to develop country-specific SoC treatment protocols and used micro-costing to estimate their costs. We compare the cost/SVR in MINMON with that of the simulated SoC, varying the expected SVR with the SoC. Results: MINMON cost/SVR (program perspective) varied by country from $1692/SVR (Thailand) to $27,632/SVR (United States). The cost/SVR (health sector perspective) ranged from $6273/SVR (South Africa) to $123,974/SVR (United States) MINMON had a lower cost/SVR than SoC across broad assumptions about SVR proportions, especially in low- and middle-income countries. In the United States-, MINMON had an appealing cost per cure compared to the SoC, unless retention on treatment fell below the SoC. Conclusions: MINMON is a cost-saving strategy for HCV treatment, particularly in low- and middle-income country settings.Keywords
This publication has 6 references indexed in Scilit:
- A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trialThe Lancet Gastroenterology & Hepatology, 2022
- Impact of COVID-19 on global HCV elimination effortsJournal of Hepatology, 2021
- Global real‐world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohortsLiver International, 2020
- Real-world Effectiveness of Sofosbuvir/Velpatasvir for Treatment of Chronic Hepatitis C in British Columbia, Canada: A Population-Based Cohort StudyOpen Forum Infectious Diseases, 2020
- Cost-effectiveness of hepatitis C treatment using generic direct-acting antivirals available in IndiaPLOS ONE, 2017
- Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalenceHepatology, 2013